List of Tables
Table 1. Global Long-acting Antipsychotic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Long-acting Antipsychotic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Long-acting Antipsychotic Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Long-acting Antipsychotic Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Long-acting Antipsychotic Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Long-acting Antipsychotic Sales by Region (2020-2025) & (K Units)
Table 8. Global Long-acting Antipsychotic Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Long-acting Antipsychotic Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Long-acting Antipsychotic Sales Share by Manufacturers (2020-2025)
Table 12. Global Long-acting Antipsychotic Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Long-acting Antipsychotic Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Long-acting Antipsychotic by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Long-acting Antipsychotic as of 2024)
Table 16. Global Long-acting Antipsychotic Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Long-acting Antipsychotic Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Long-acting Antipsychotic Manufacturing Base and Headquarters
Table 19. Global Long-acting Antipsychotic Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Long-acting Antipsychotic Sales by Type (2020-2025) & (K Units)
Table 23. Global Long-acting Antipsychotic Sales by Type (2026-2031) & (K Units)
Table 24. Global Long-acting Antipsychotic Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Long-acting Antipsychotic Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Long-acting Antipsychotic ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Long-acting Antipsychotic Sales by Application (2020-2025) & (K Units)
Table 29. Global Long-acting Antipsychotic Sales by Application (2026-2031) & (K Units)
Table 30. Long-acting Antipsychotic High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Long-acting Antipsychotic Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Long-acting Antipsychotic Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Long-acting Antipsychotic ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Long-acting Antipsychotic Growth Accelerators and Market Barriers
Table 37. North America Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Long-acting Antipsychotic Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Long-acting Antipsychotic Growth Accelerators and Market Barriers
Table 40. Europe Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Long-acting Antipsychotic Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Long-acting Antipsychotic Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Long-acting Antipsychotic Growth Accelerators and Market Barriers
Table 45. Southeast Asia Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Long-acting Antipsychotic Investment Opportunities and Key Challenges
Table 47. Central and South America Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Long-acting Antipsychotic Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Long-acting Antipsychotic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Oakwood Labs Corporation Information
Table 51. Oakwood Labs Description and Major Businesses
Table 52. Oakwood Labs Product Models, Descriptions and Specifications
Table 53. Oakwood Labs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Oakwood Labs Sales Value Proportion by Product in 2024
Table 55. Oakwood Labs Sales Value Proportion by Application in 2024
Table 56. Oakwood Labs Sales Value Proportion by Geographic Area in 2024
Table 57. Oakwood Labs Long-acting Antipsychotic SWOT Analysis
Table 58. Oakwood Labs Recent Developments
Table 59. Teva Corporation Information
Table 60. Teva Description and Major Businesses
Table 61. Teva Product Models, Descriptions and Specifications
Table 62. Teva Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Teva Sales Value Proportion by Product in 2024
Table 64. Teva Sales Value Proportion by Application in 2024
Table 65. Teva Sales Value Proportion by Geographic Area in 2024
Table 66. Teva Long-acting Antipsychotic SWOT Analysis
Table 67. Teva Recent Developments
Table 68. MedinCell Corporation Information
Table 69. MedinCell Description and Major Businesses
Table 70. MedinCell Product Models, Descriptions and Specifications
Table 71. MedinCell Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. MedinCell Sales Value Proportion by Product in 2024
Table 73. MedinCell Sales Value Proportion by Application in 2024
Table 74. MedinCell Sales Value Proportion by Geographic Area in 2024
Table 75. MedinCell Long-acting Antipsychotic SWOT Analysis
Table 76. MedinCell Recent Developments
Table 77. Janssen Corporation Information
Table 78. Janssen Description and Major Businesses
Table 79. Janssen Product Models, Descriptions and Specifications
Table 80. Janssen Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Janssen Sales Value Proportion by Product in 2024
Table 82. Janssen Sales Value Proportion by Application in 2024
Table 83. Janssen Sales Value Proportion by Geographic Area in 2024
Table 84. Janssen Long-acting Antipsychotic SWOT Analysis
Table 85. Janssen Recent Developments
Table 86. Otsuka America Pharmaceutical, Inc. Corporation Information
Table 87. Otsuka America Pharmaceutical, Inc. Description and Major Businesses
Table 88. Otsuka America Pharmaceutical, Inc. Product Models, Descriptions and Specifications
Table 89. Otsuka America Pharmaceutical, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Product in 2024
Table 91. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Application in 2024
Table 92. Otsuka America Pharmaceutical, Inc. Sales Value Proportion by Geographic Area in 2024
Table 93. Otsuka America Pharmaceutical, Inc. Long-acting Antipsychotic SWOT Analysis
Table 94. Otsuka America Pharmaceutical, Inc. Recent Developments
Table 95. Lundbeck Corporation Information
Table 96. Lundbeck Description and Major Businesses
Table 97. Lundbeck Product Models, Descriptions and Specifications
Table 98. Lundbeck Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Lundbeck Recent Developments
Table 100. Eli Lilly Corporation Information
Table 101. Eli Lilly Description and Major Businesses
Table 102. Eli Lilly Product Models, Descriptions and Specifications
Table 103. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Eli Lilly Recent Developments
Table 105. Alkermes Corporation Information
Table 106. Alkermes Description and Major Businesses
Table 107. Alkermes Product Models, Descriptions and Specifications
Table 108. Alkermes Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Alkermes Recent Developments
Table 110. Par Pharmaceutical Corporation Information
Table 111. Par Pharmaceutical Description and Major Businesses
Table 112. Par Pharmaceutical Product Models, Descriptions and Specifications
Table 113. Par Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. Par Pharmaceutical Recent Developments
Table 115. AbbVie Corporation Information
Table 116. AbbVie Description and Major Businesses
Table 117. AbbVie Product Models, Descriptions and Specifications
Table 118. AbbVie Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. AbbVie Recent Developments
Table 120. Luye Pharmaceutical Corporation Information
Table 121. Luye Pharmaceutical Description and Major Businesses
Table 122. Luye Pharmaceutical Product Models, Descriptions and Specifications
Table 123. Luye Pharmaceutical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Luye Pharmaceutical Recent Developments
Table 125. Key Raw Materials Distribution
Table 126. Raw Materials Key Suppliers
Table 127. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 128. Milestones in Production Technology Evolution
Table 129. Distributors List
Table 130. Market Trends and Market Evolution
Table 131. Market Drivers and Opportunities
Table 132. Market Challenges, Risks, and Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Long-acting Antipsychotic Product Picture
Figure 2. Global Long-acting Antipsychotic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Aripiprazole Product Picture
Figure 4. Haloperidol Product Picture
Figure 5. Paliperidone Product Picture
Figure 6. Risperidone Product Picture
Figure 7. Olanzapine Product Picture
Figure 8. Others Product Picture
Figure 9. Global Long-acting Antipsychotic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Schizophrenia
Figure 11. Bipolar Disorder
Figure 12. Others
Figure 13. Long-acting Antipsychotic Report Years Considered
Figure 14. Global Long-acting Antipsychotic Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 16. Global Long-acting Antipsychotic Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Long-acting Antipsychotic Revenue Market Share by Region (2020-2031)
Figure 18. Global Long-acting Antipsychotic Sales (2020-2031) & (K Units)
Figure 19. Global Long-acting Antipsychotic Sales (CAGR) by Region (2020-2031) (K Units)
Figure 20. Global Long-acting Antipsychotic Sales Market Share by Region (2020-2031)
Figure 21. Top 5 and Top 10 Manufacturers Long-acting Antipsychotic Sales Volume Market Share in 2024
Figure 22. Global Long-acting Antipsychotic Revenue Market Share Ranking (2024)
Figure 23. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 24. Aripiprazole Revenue Market Share by Manufacturer in 2024
Figure 25. Haloperidol Revenue Market Share by Manufacturer in 2024
Figure 26. Paliperidone Revenue Market Share by Manufacturer in 2024
Figure 27. Risperidone Revenue Market Share by Manufacturer in 2024
Figure 28. Olanzapine Revenue Market Share by Manufacturer in 2024
Figure 29. Others Revenue Market Share by Manufacturer in 2024
Figure 30. Global Long-acting Antipsychotic Sales Market Share by Type (2020-2031)
Figure 31. Global Long-acting Antipsychotic Revenue Market Share by Type (2020-2031)
Figure 32. Global Long-acting Antipsychotic Sales Market Share by Application (2020-2031)
Figure 33. Global Long-acting Antipsychotic Revenue Market Share by Application (2020-2031)
Figure 34. North America Long-acting Antipsychotic Sales YoY (2020-2031) & (K Units)
Figure 35. North America Long-acting Antipsychotic Revenue YoY (2020-2031) & (US$ Million)
Figure 36. North America Top 5 Manufacturers Long-acting Antipsychotic Sales Revenue (US$ Million) in 2024
Figure 37. North America Long-acting Antipsychotic Sales Volume (K Units) by Type (2020- 2031)
Figure 38. North America Long-acting Antipsychotic Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 39. North America Long-acting Antipsychotic Sales Volume (K Units) by Application (2020-2031)
Figure 40. North America Long-acting Antipsychotic Sales Revenue (US$ Million) by Application (2020-2031)
Figure 41. US Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 42. Canada Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 43. Mexico Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 44. Europe Long-acting Antipsychotic Sales YoY (2020-2031) & (K Units)
Figure 45. Europe Long-acting Antipsychotic Revenue YoY (2020-2031) & (US$ Million)
Figure 46. Europe Top 5 Manufacturers Long-acting Antipsychotic Sales Revenue (US$ Million) in 2024
Figure 47. Europe Long-acting Antipsychotic Sales Volume (K Units) by Type (2020-2031)
Figure 48. Europe Long-acting Antipsychotic Sales Revenue (US$ Million) by Type (2020-2031)
Figure 49. Europe Long-acting Antipsychotic Sales Volume (K Units) by Application (2020-2031)
Figure 50. Europe Long-acting Antipsychotic Sales Revenue (US$ Million) by Application (2020-2031)
Figure 51. Germany Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 52. France Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 53. U.K. Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 54. Italy Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 55. Russia Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 56. Asia-Pacific Long-acting Antipsychotic Sales YoY (2020-2031) & (K Units)
Figure 57. Asia-Pacific Long-acting Antipsychotic Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Asia-Pacific Top 8 Manufacturers Long-acting Antipsychotic Sales Revenue (US$ Million) in 2024
Figure 59. Asia-Pacific Long-acting Antipsychotic Sales Volume (K Units) by Type (2020- 2031)
Figure 60. Asia-Pacific Long-acting Antipsychotic Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 61. Asia-Pacific Long-acting Antipsychotic Sales Volume (K Units) by Application (2020-2031)
Figure 62. Asia-Pacific Long-acting Antipsychotic Sales Revenue (US$ Million) by Application (2020-2031)
Figure 63. Indonesia Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 64. Japan Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 65. South Korea Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 66. China Taiwan Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 67. India Long-acting Antipsychotic Revenue (2020-2031) & (US$ Million)
Figure 68. Central and South America Long-acting Antipsychotic Sales YoY (2020-2031) & (K Units)
Figure 69. Central and South America Long-acting Antipsychotic Revenue YoY (2020-2031) & (US$ Million)
Figure 70. Central and South America Top 5 Manufacturers Long-acting Antipsychotic Sales Revenue (US$ Million) in 2024
Figure 71. Central and South America Long-acting Antipsychotic Sales Volume (K Units) by Type (2021-2031)
Figure 72. Central and South America Long-acting Antipsychotic Sales Revenue (US$ Million) by Type (2020-2031)
Figure 73. Central and South America Long-acting Antipsychotic Sales Volume (K Units) by Application (2020-2031)
Figure 74. Central and South America Long-acting Antipsychotic Sales Revenue (US$ Million) by Application (2020-2031)
Figure 75. Brazil Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 76. Argentina Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 77. Middle East, and Africa Long-acting Antipsychotic Sales YoY (2020-2031) & (K Units)
Figure 78. Middle East and Africa Long-acting Antipsychotic Revenue YoY (2020-2031) & (US$ Million)
Figure 79. Middle East and Africa Top 5 Manufacturers Long-acting Antipsychotic Sales Revenue (US$ Million) in 2024
Figure 80. Middle East and Africa Long-acting Antipsychotic Sales Volume (K Units) by Type (2021-2031)
Figure 81. South America Long-acting Antipsychotic Sales Revenue (US$ Million) by Type (2020-2031)
Figure 82. Middle East and Africa Long-acting Antipsychotic Sales Volume (K Units) by Application (2020-2031)
Figure 83. Middle East and Africa Long-acting Antipsychotic Sales Revenue (US$ Million) by Application (2020-2031)
Figure 84. GCC Countries Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 85. Turkey Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 86. Egypt Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 87. South Africa Long-acting Antipsychotic Revenue (2020-2025) & (US$ Million)
Figure 88. Long-acting Antipsychotic Industry Chain Mapping
Figure 89. Regional Long-acting Antipsychotic Manufacturing Base Distribution (%)
Figure 90. Global Long-acting Antipsychotic Production Market Share by Region (2020-2031)
Figure 91. Long-acting Antipsychotic Production Process
Figure 92. Regional Long-acting Antipsychotic Production Cost Structure
Figure 93. Channels of Distribution (Direct Vs Distribution)
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed
